These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38042335)

  • 21. Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator.
    Nguyen TN; Trocio J; Kowal S; Ferrufino CP; Munakata J; South D
    Am Health Drug Benefits; 2016 Dec; 9(9):475-485. PubMed ID: 28465775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.
    Blommestein HM; Franken MG; Uyl-de Groot CA
    Pharmacoeconomics; 2015 Jun; 33(6):551-60. PubMed ID: 25644460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?
    Barr HK; Guggenbickler AM; Hoch JS; Dewa CS
    Curr Oncol; 2023 Apr; 30(4):4078-4093. PubMed ID: 37185423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence.
    van Gils CW; de Groot S; Redekop WK; Koopman M; Punt CJ; Uyl-de Groot CA
    Pharmacoeconomics; 2013 Aug; 31(8):703-18. PubMed ID: 23657918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers.
    Alshreef A; Latimer N; Tappenden P; Wong R; Hughes D; Fotheringham J; Dixon S
    Med Decis Making; 2019 Nov; 39(8):910-925. PubMed ID: 31646932
    [No Abstract]   [Full Text] [Related]  

  • 27. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.
    Williams C; Lewsey JD; Mackay DF; Briggs AH
    Med Decis Making; 2017 May; 37(4):427-439. PubMed ID: 27698003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention.
    Paget MA; Tockhorn-Heidenreich A; Belger M; Chartier F; Lantéri-Minet M
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1321-1330. PubMed ID: 38058137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of real-world evidence in meta-analyses and cost-effectiveness models.
    Bowrin K; Briere JB; Levy P; Toumi M; Millier A
    J Med Econ; 2020 Oct; 23(10):1053-1060. PubMed ID: 32657189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights.
    Getz K; Mamtani R; Hubbard RA
    J Biopharm Stat; 2022 Jan; 32(1):191-203. PubMed ID: 34756156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network.
    Freeman SC; Cooper NJ; Sutton AJ; Crowther MJ; Carpenter JR; Hawkins N
    Stat Methods Med Res; 2022 May; 31(5):839-861. PubMed ID: 35044255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
    Connock M; Juarez-Garcia A; Jowett S; Frew E; Liu Z; Taylor RJ; Fry-Smith A; Day E; Lintzeris N; Roberts T; Burls A; Taylor RS
    Health Technol Assess; 2007 Mar; 11(9):1-171, iii-iv. PubMed ID: 17313907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
    Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
    Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
    van Kampen RJW; Ramaekers BLT; Lobbezoo DJA; de Boer M; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FPJ; van Riel JMG; Peters NAJB; Tjan-Heijnen VCG; Joore MA
    Eur J Cancer; 2017 Jul; 79():238-246. PubMed ID: 28245951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
    Chew DS; Li Y; Bigelow R; Cowper PA; Anstrom KJ; Daniels MR; Davidson-Ray L; Hernandez AF; O'Connor CM; Armstrong PW; Mark DB;
    Circulation; 2023 Oct; 148(14):1087-1098. PubMed ID: 37671551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.
    Che Z; Green N; Baio G
    Med Decis Making; 2023 Apr; 43(3):299-310. PubMed ID: 36314662
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.